After 10 days of treatment, both groups showed a significant reduction in complaints: the total clinical score developed from points to points in group 1 and from points to points in group 2.
The ENT examination showed a decrease in the severity of inflammatory events in the nasal cavity (). Cytological evaluation of nasal secretion in both groups revealed an increase in the relative count of eosinophils and the absolute count of leukocytes. This was mainly due to an increase in neutrophils. A significant decrease in the amount of secretory IgE was observed in group 1 and group 2 ().
Group 1: ENS plus antihistamines and/or cromoglicate
A decrease in the severity of AR symptoms on the TNSS scale in both groups ( points in group 1 and points in group 2) was observed.
As a result of combination therapy in both groups, a marked decrease in both clinical and laboratory activities of inflammation was achieved between visits 1 and 3: a decrease in eosinophil count ( in group 1 and in group 2); a decrease in the overall assessment score of the rhinocytogram ( in group 1 and in group 2); a decrease in the score of AR exacerbations according to the anterior rhinoscopy data ( in group 1 and in group 2).
Most of the patients (20/34) benefited from treatment with ENS. In 6 out of 34 participants, the disease worsened and 8 patients expressed no difference. Thus, there were 2.6 and 3.3 times more patients in whom use of ENS spray led to decreases in symptoms.
All patients except one showed a decrease in the intensity of all clinical symptoms of AR.
After a week of use of ENS, the range of eosinophils in the rhinocytogram has not changed. However, the average number of eosinophils tended to decrease from to
